We recently shared preclinical data on seribantumab in NRG1 fusion PDX models at EORTC-NCI-AACR 2020. Here’s a closer look at what PDX models are, and why they’re such important tools for developing precision medicines for cancer:
Like This Content?
Go even deeper in “NRG1 fusions – a (PDX) model challenge” by Shawn Leland, our Founder and CEO.
Read the Full Article